Can infliximab (Remicade) and iron supplementation be administered simultaneously?

Yes, infliximab and iron supplementation can be administered simultaneously

Based on available evidence, you can safely give infliximab (Remicade) and intravenous iron in the same treatment session, but oral iron supplementation should be approached with caution in patients with active inflammation. 1

Intravenous Iron with Infliximab: Safe and Practical

A prospective pilot study specifically evaluated the safety of administering ferric carboxymaltose (FCM) immediately after infliximab infusion in IBD patients with iron deficiency 1. Key findings include:

• No adverse events were reported during or after combined administration (assessed at end of infusion, 30 minutes, 7 days, and 8 weeks)
• Effective correction of iron deficiency and iron-restricted anemia occurred
• Cost savings of approximately €177 per patient compared to separate-day administration
• Improved treatment adherence with single-session approach

The Physiologic Rationale

Infliximab actually increases functional iron deficiency by raising erythropoietin (EPO) and soluble transferrin receptor (sTFR) levels 2. This creates an increased demand for iron that IV supplementation can address. After combined treatment with IV iron and infliximab, EPO and sTFR levels normalize, restoring the functional iron deficiency induced by infliximab 2.

Oral Iron: Exercise Caution

Oral iron supplementation during active IBD inflammation may worsen disease activity, even in patients receiving anti-TNF therapy 3. An experimental study demonstrated that:

• Both infliximab and adalimumab failed to ameliorate inflammation aggravated by oral iron
• Moderate to high oral iron doses significantly worsened inflammation despite reduction in TNF-α levels
• This effect occurred even with concurrent biologic therapy 3

Clinical Approach Algorithm

For patients with active IBD on infliximab:

1. Screen for iron deficiency using ferritin, transferrin saturation, and hepcidin (if available) 4
2. If iron deficient:
   • Choose IV iron (ferric carboxymaltose or iron sucrose) over oral formulations
   • Administer immediately after infliximab infusion in the same session 1
   • Monitor for infusion reactions (though risk is minimal)
3. Avoid oral iron in patients with active inflammation or moderate-to-severe disease 3

For patients in remission:

• Oral iron may be considered, though IV remains preferred for better absorption and tolerability 5
• Monitor disease activity if using oral supplementation

Important Caveats

The FDA label for Remicade does not specifically address iron co-administration 6. However, it emphasizes monitoring during infusions and having emergency medications available for any infusion reactions. The lack of specific contraindication, combined with positive safety data from clinical studies, supports the practice.

Hepcidin levels decrease during successful induction therapy 4, which may improve iron bioavailability. This suggests timing iron supplementation after initiating infliximab may be particularly effective.

The evidence consistently shows that anti-TNF therapy alone improves anemia in IBD patients 7, but iron supplementation provides additional benefit, particularly in severely anemic patients (hemoglobin <9 g/dL) 7.